1-2 of 2
Keywords: Goserelin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis

Available to Purchase
Subject Area:
Further Areas
Yuanshan Cui, Huantao Zong, Huilei Yan, Nan Li, Yong Zhang
Journal: Urologia Internationalis
Urol Int (2014) 93 (2): 152–159.
https://doi.org/10.1159/000356272
Published Online: 01 March 2014
...: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Results: Three publications involving a total of 466 patients were used in the analysis, including three RCTs that compared degarelix with goserelin plus bicalutamide therapy for PCa over 12 weeks. For the comparison of degarelix with goserelin...
View article titled, Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis
Open the PDF for Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis in another window
Journal Articles

Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)

Available to Purchase
Subject Area:
Further Areas
John Anderson, Ghandi Al-Ali, Manfred Wirth, Joan Benejam Gual, Francisco Gomez Veiga, Enrico Colli, Egbert van der Meulen, Bo-Eric Persson
Journal: Urologia Internationalis
Urol Int (2013) 90 (3): 321–328.
https://doi.org/10.1159/000345423
Published Online: 15 December 2012
... to prostate cancer (PrCa). Methods: Patients were randomised to degarelix 240/80 mg or goserelin 3.6 mg + bicalutamide flare protection (G+B); both treatments were administered for 3 months. The primary endpoint was change in International Prostate Symptom Score (IPSS) at week 12 compared with baseline...
View article titled, Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)
Open the PDF for Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233) in another window